395 Results for "

(R)-AS-1

" in MedChemExpress (MCE) Product Catalog:
Products (395)

395 Results for "(R)-AS-1" in MCE Product Catalog:

Cat. No.: HY-168773
CAS No.: 2506367-95-7
Target:  

EAAT

Research Areas:  

Neurological Disease

(R)-AS-1 is a selective positive allosteric modulator of the excitatory amino acid transporter 2 (EAAT2), with an EC50 of 11 nM. (R)-AS-1 (at doses of 60 and 90 mg/kg) increases spontaneous locomotor activity in mice. Additionally, it demonstrates anticonvulsant activity in mouse models of seizures induced by maximal electroshock (MES), pentylenetetrazole (PTZ), or electrical stimuli (32 or 44 mA), with ED50s of 66.3, 36.3, 15.6, and 41.6 mg/kg, respectively. (R)-AS-1 can be used in neurological disease research [1].
loading...
    loading...
202
202 Publications Verification
Cat. No.: HY-15772
CAS No.: 1421373-65-0
Purity:  99.92%
Synonyms: AZD-9291; Mereletinib
Target:  

EGFR

Research Areas:  

Cancer

Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer [1].
loading...
    loading...
202
202 Publications Verification
Cat. No.: HY-15772A
CAS No.: 1421373-66-1
Purity:  99.97%
Synonyms: AZD-9291 mesylate; Mereletinib mesylate
Target:  

EGFR

Research Areas:  

Cancer

Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer [1].
loading...
    loading...
38
38 Cited Publications
Cat. No.: HY-12215
CAS No.: 1454846-35-5
Purity:  99.92%
Synonyms: PF-06463922
Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive ROS1/ALK inhibitor with anticancer activity. Lorlatinib has Kis of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK L1196M, respectively. Lorlatinib targets to EML4-ALK, and inhibits ALK phosphorylation with IC50s of 15-43 nM (ALK L1196), 14-80 nM (ALK G1269A), 38-50 nM (ALK 1151Tins), 77-113 nM (ALK G1202R), respectively .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-13038A
CAS No.: 901119-35-5
Purity:  99.70%
Synonyms: R788
Target:  

Syk FLT3

Research Areas:  

Inflammation/Immunology Cancer

Fostamatinib (R788) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-13038
CAS No.: 1025687-58-4
Purity:  99.88%
Synonyms: R788Disodium
Target:  

Syk FLT3

Research Areas:  

Inflammation/Immunology Cancer

Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-13038B
CAS No.: 914295-16-2
Purity:  99.51%
Synonyms: R788 disodium hexahydrate
Target:  

Syk FLT3

Research Areas:  

Inflammation/Immunology Cancer

Fostamatinib (R788) disodium hexahydrate is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-50905
CAS No.: 405169-16-6
Synonyms: CHIR-258; TKI258
Target:  

FLT3 c-Kit FGFR VEGFR PDGFR c-Fms

Research Areas:  

Cancer

Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity [1] .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-13030A
CAS No.: 1268524-71-5
Purity:  99.66%
Research Areas:  

Cancer

(R)-(-)-JQ1 Enantiomer is the stereoisomer of (+)-JQ1. (+)-JQ1 potently decreases expression of both BRD4 target genes, whereas (R)-(-)-JQ1 Enantiomer has no effect.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-101116
CAS No.: 488097-06-9
Purity:  99.67%
Target:  

GCGR

Research Areas:  

Metabolic Disease

GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM [1].
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P1110
CAS No.: 185413-30-3
Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM). AF12198 inhibits IL-1-induced IL-8 production (IC50=25 nM) and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression (IC50=9 nM) in vitro. AF12198 has anti-inflammatory activities and blocks responses to IL-1 in vivo [1].
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-122575
CAS No.: 4431-00-9
Purity:  ≥92.0%
Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive P2X1Rs and P2X3Rs, with IC50s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively . Aurintricarboxylic acid is a potent anti-influenza agent by directly inhibiting the neuraminidase . Aurintricarboxylic acid is an inhibitor of topoisomerase II and apoptosis . Aurintricarboxylic acid is a selective inhibitor of the TWEAK-Fn14 signaling pathway . Aurintricarboxylic acid also acts as a cystathionine-lyase (CSE) inhibitor with an IC50 of 0.6 μM . Aurintricarboxylic acid is a modifier of miRNAs that regulate miRNA function, with an IC50 of 0.47 µM .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-113402
CAS No.: 636-58-8
Purity:  95.20%
Synonyms: γ-Glu-Cys
Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease [1] .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-113402A
CAS No.: 283159-88-6
Purity:  95.20%
Synonyms: γ-Glu-Cys TFA
Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease [1] .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-145237
CAS No.: 2891606-02-1
Purity:  99.81%
BM213 is a selective C5aR agonist, with an EC50 of 59 nM. BM213 specifically activates the C5a-C5aR1 axis, which in turn promotes neutrophil extracellular trap (NET) formation and exacerbates inflammatory responses. BM213 significantly induces ventricular dilationin, promotes myocardial ROS production, and induces cardiomyocyte apoptosis in rats. BM213 can be used for the study of myocardial ischemia/reperfusion (I/R) injury .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-153918
CAS No.: 2955634-67-8
Purity:  99.50%
Target:  

Androgen Receptor

Research Areas:  

Cancer

(R)-SKBG-1 is a covalent inhibitor targeting the RNA binding protein NONO. (R)-SKBG-1 can reduce the expression of androgen receptor (AR) and its splice variants, inhibiting cancer cell proliferation. (R)-SKBG-1 inhibits androgen receptor expression with IC50 of 3.1 μM and 5.5 μM for AR-FL mRNA and AR-V7 mRNA, respectively. (R)-SKBG-1 interferes with the gene regulatory network of cancer cells and inhibits cancer cell growth by stabilizing the interaction between NONO and mRNA. (R)-SKBG-1 can be used in the study of cancers related to NONO dysfunction, such as prostate cancer [1] .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-112484
CAS No.: 878451-87-7
Purity:  99.52%
Target:  

Organoid

Research Areas:  

Cancer

RS-246204 is a R-spondin-1 substitute compound that is able initiate small intestinal organoids without the use of the R-spondin-1 protein.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12405
CAS No.: 127060-75-7
Purity:  99.84%
Synonyms: CGP42112A
CGP-42112 (CGP-42112A) is a potent Angiotensin-II subtype 2 receptor(AT2 R) agonist .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B0025
CAS No.: 83480-29-9
Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis [1].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108618
CAS No.: 686770-80-9
Purity:  99.42%
Research Areas:  

Endocrinology

BC11-38 is a potent, selective, and biologically active PDE11 inhibitor, with IC50s of 0.28 µM and >100 µM for PDE11 and PDE1-10, respectively. BC11-38 elevates cAMP levels, PKA-mediated ATF-1 phosphorylation, and cortisol production in H295R cells .
loading...
    loading...